Contains An Animal Extract Patents (Class 435/408)
  • Patent number: 6383805
    Abstract: A method and a medium for culturing epithelial cells of both normal and malignant origin is provided. The method entails physically disaggregating tissue samples, placing the resulting fragments onto a surface comprised of basement membrane matrix components, and culturing the tissue in a medium containing preselected fetal and newborn calf sera and rat sera. Both primary explant cell cultures and cell lines, which are long-lived and particularly suitable for further study, are produced. The cultured primary explant cells undergo differentiation to form complex structures resembling those seen in vivo.
    Type: Grant
    Filed: April 11, 2000
    Date of Patent: May 7, 2002
    Assignee: University of Pittsburgh
    Inventor: Jean J. Latimer
  • Patent number: 6376238
    Abstract: The present invention is directed to a culture medium for neurons prepared by adding albumin to a culture supernatant obtained from a culture of primary astroglial cells in a trophic medium supplemented with insulin and transferrin. The culture medium of the present invention makes it possible to culture central nerve cells consistently. When nerve cells are cultured at a low cell density, excellent neurite extension is obtained, and synapses are formed rapidly. On the other hand, when nerve cells are cultured at a high cell density, long-term stability of cells that have formed neuronetworks can be obtained.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: April 23, 2002
    Assignee: Sumitomo Bakelite Co., Ltd.
    Inventor: Yoshiaki Watanabe
  • Patent number: 6255109
    Abstract: Nitric oxide adversely affects survival and development of cells such as oocytes and embryos in vitro, particularly in a co-culture system. The addition of a nitric oxide inhibitor such as hemoglobin to such systems eliminates this toxic effect, and promotes mammalian oocytes, embryos, or other cells in vitro.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: July 3, 2001
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: William Hansel, Jeong-Mook Lim
  • Patent number: 6245567
    Abstract: The present invention concerns products and methods particularly useful for activating and analyzing non-dividing cell nuclei. The featured products include activating egg extracts, cytostatic factor (CSF) extracts, kits containing these extracts, and a microchamber microscope slide useful in analyzing nucleus activation.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: June 12, 2001
    Assignee: Brandeis University
    Inventor: Lawrence J. Wangh
  • Patent number: 6228640
    Abstract: A method is described whereby a dendritic cell derived from the CD34 hematopoietic cell lineage is directed to become a super antigen presenting cell that has been pulsed with tumor cell RNA or RNA expression products. The protocol provides for programming the maturation of dendritic cells to become antigen presenting cells. The protocol further provides for isolating tumor cell RNA from biopsy material that has been prepared in pariffin block storage. The directed dendritic cell is provided with a plurality of tumor markers by using tumor RNA in toto or the poly A+RNA fraction. Once activated the dendritic cells are incubated with T4 and T8 lymphocytes to stimulate and sensitize the T lymphocytes which upon introduction either into a donor host or a nondonor recipient will provide immune response protection.
    Type: Grant
    Filed: February 3, 1998
    Date of Patent: May 8, 2001
    Inventors: Cem Cezayirli, Mel Silvers
  • Patent number: 6214567
    Abstract: A spontaneously immortalized human keratinocyte cell line is disclosed. In a preferred embodiment, this cell line is ATCC 12191. In another embodiment of the invention, a method of assaying the effect of a test tumor cell modulation agent is disclosed. The method comprises the steps of obtaining a human stratified squamous epithelial cell culture, wherein the culture comprises human malignant squamous epithelial cells and spontaneously immortalized human keratinocytes, wherein the culture forms a reconstituted epidermis. One then treats the epidermis with a test tumor cell modulation agent and evaluates the growth of the malignant cells within the epidermis.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: April 10, 2001
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: B. Lynn Allen-Hoffmann, Michael A. Pickart
  • Patent number: 6146890
    Abstract: A method of cultivating macrophages from blood, including collecting a quantity of blood, fractionating the quantity of blood into a plasma fraction, a white blood cell fraction generally including monocytes, and a red blood cell fraction, segregating the white blood cell fraction from the plasma fraction, while allowing a portion of the red blood cell fraction to remain mixed with the white blood cell fraction, the portion of the red blood cell fraction being less than the white blood cell fraction, and inducing differentiation of the monocytes into macrophages and lysing at least part of the portion of the red blood cell fraction mixed with the white blood cell fraction by causing an osmotic shock to the white blood cell fraction and the red blood cell fraction
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: November 14, 2000
    Inventor: David Danon
  • Patent number: 6130086
    Abstract: The present invention aims to provide a medium composition for in vitro fertilization, in particular, a composition usable in the culture of ova or early embryos which are fertilized eggs, the preparation or culture of sperm, and the pre-treatment of ova or sperm.The composition comprises, as its essential components, L-phenylalanine, L-tryptophan, L-lysine, L-threonine, L-valine, L-methionine, L-isoleucine, L-leucine, L-proline, glycine, L-alanine, L-tyrosine, L-histidine, L-arginine, L-taurine, L-aspartic acid, L-serine, L-asparagine, L-glutamic acid, L-glutamine and L-cystine, provided that at least a part of the L-cystine may be replaced by L-cysteine.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: October 10, 2000
    Assignee: Fuso Pharmaceutical Industries, Ltd.
    Inventors: Teruki Nakazawa, Hiromasa Araki, Yuichiro Kishi, Sanji Shinoda, Moriyuki Yamada, Kazutomo Ohashi
  • Patent number: 6114168
    Abstract: A culture medium for culturing chicken embryonic stem (ES) cells is disclosed. The culture medium is used for supporting avian ES cell cultures. The components of the avian ES cell media include cytokines, fibroblast growth factors, insulin-like growth factors and stem cell growth factors and anti-retinoic acid antibody. The culture medium is substantially free of active retinoic acid. A method for culturing avian ES cells and the resulting products are also disclosed.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: September 5, 2000
    Assignees: Institute National de la Recherche Agronomique, Centre National de la Recherche Scientifique (CNRS), Ecole Normale Superieure de Lyon
    Inventors: Jacques Samarut, Bertrand Pain
  • Patent number: 6103523
    Abstract: The present invention relates to a rabbit embryonic stem (ES) cell line, comprising at least 70%, preferably 80 to 90% undifferentiated cells and obtainable by isolating the inner cell mass of 5.5 days postcoitus blastocysts and culturing them on feeder cells in rabbit ES medium. The invention further relates to further optimization of derivation and maintainance of the cell line and to the use thereof in inter alia generation of chimeric rabbits.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: August 15, 2000
    Assignee: Thromb-X N.V.
    Inventors: Randall Moreadith, Luc Schoonjans
  • Patent number: 6087174
    Abstract: The present invention provides a method of treating cancer comprising (a) obtaining a tumor cell line, (b) modifying the tumor cell line to render it capable of producing an increased level of a cytokine relative to the unmodified tumor cell line, and (c) administering the tumor cell line to a mammalian host having at least one tumor that is the same type of tumor as that from which the tumor cell line was obtained, wherein the tumor cell line is allogeneic and is not MHC-matched to the host. The present invention also provides a pancreatic tumor cell line, a method and medium for obtaining such a tumor cell line, and a composition comprised of cells of a purified pancreatic tumor cell line.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: July 11, 2000
    Assignee: Johns Hopkins University, School of Medicine
    Inventors: Elizabeth M. Jaffee, Drew M. Pardoll, Hyam I. Levitsky
  • Patent number: 6074874
    Abstract: A method and a medium for culturing epithelial cells of both normal and malignant origin is provided. The method entails physically disaggregating tissue samples, placing the resulting fragments onto a surface comprised of basement membrane matrix components, and culturing the tissue in a medium containing preselected fetal and newborn calf sera and rat sera. Both primary explant cell cultures and cell lines, which are long-lived and particularly suitable for further study, are produced. The cultured primary explant cells undergo differentiation to form complex structures resembling those seen in vivo.
    Type: Grant
    Filed: August 29, 1997
    Date of Patent: June 13, 2000
    Assignee: University of Pittsburgh
    Inventor: Jean J. Latimer
  • Patent number: 6054317
    Abstract: A system for the culture of eukaryotic cells of marine invertebrates employing a culture medium containing a mixture of sodium, magnesium, chlorine, potassium, calcium, bromine, and sulfate is disclosed, as well as a system for the cryopreservation of such cells in which the medium contains dimethyl sulfoxide.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: April 25, 2000
    Inventor: Peter McMahon
  • Patent number: 5916809
    Abstract: Provided is a medium for culturing normal human epidermal melanocytes in vitro. The medium comprises a basal medium for culturing animal cells, Ca.sup.2+ at a final concentration of between about 0.15 mM and about 1.2 mM and Mg.sup.2+ at a final concentration of 1.2 mM and 6 mM or Ca.sup.2+ at a final concentration of between about 0.9 mM and about 1.2 mM and Mg.sup.2+ at a final concentration between about 0.6 mM and 6.0 mM and 0.001 to 0.1% scrum (v/v). The medium can promote both dendrite formation and proliferation of the cells.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: June 29, 1999
    Assignee: NEC Corporation
    Inventors: Hiroshi Yanase, Hisashi Torishima, Ryohei Yamamoto
  • Patent number: 5912177
    Abstract: Haematopoietic stem cells (which term includes early progenitor cells) are immobilized on a substrate coated with a fibrin matrix and including a substance capable of both binding to the fibrin matrix and also having an RGD amino acid sequence for binding to the stem cells. The substance may be fibronectin or thrombospondin. The substrate is generally in the form of a closed bag formed of a carbon dioxide-permeable and oxygen-permeable plastics material which allows culturing of the stem cells. The cultured stem cells may re-engraft a patient following chemotherapy or to correct haemotological deficiencies. Stem cells may be harvested from peripheral blood onto the coated substrate. The stem cells in contact with the coated substrate are good candidates for gene therapy to introduce a heterologous gene e.g. employing a transfection vector.
    Type: Grant
    Filed: April 8, 1997
    Date of Patent: June 15, 1999
    Assignee: Common Services Agency
    Inventors: Marc Leighton Turner, William Gerrard Murphy
  • Patent number: 5910443
    Abstract: The present invention relates to a culture of human olfactory neurons. The neurons may display a normal neuronal pathology or a pathology characteristic of a generalized central nervous system disease. The cultured neurons can be used for neurotoxicity tests, screening for therapeutic drugs and anti-viral agents.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: June 8, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventor: Hyden G. Coon
  • Patent number: 5888816
    Abstract: The present invention provides a method for producing an expanded, enriched, non-transformed human cell culture of human pancreatic, thyroid or parathyroid endocrine cells and other types of cells which comprises (1) preparing partially purified, minced tissue that includes a desired type of cells; (2) concentrating the desired cells; (3) resuspending the concentrated cells in a growth medium which selects in favor of the desired cells and in which those cells are proliferated without being transformed and differentiated functions are retained through periodic passaging; (4) culturing the resuspended cells in the growth medium to effect sustained cell division; and (5) passaging the cultured cells periodically to expand the culture.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 30, 1999
    Assignee: Human Cell Cultures Inc.
    Inventors: Hayden G. Coon, Francesco Saverio Ambesi-Impiombato, Francesco Curcio
  • Patent number: 5866414
    Abstract: A cell culture growth substrate comprising submucosal tissue of a warm-blooded vertebrate and a method for culturing eukaryotic cells are described. Submucosal tissue used in accordance with the present invention supports the proliferation and differentiation of eukaryotic cells when said cells are contacted with submucosal tissue under conditions conducive to cell proliferation.
    Type: Grant
    Filed: September 19, 1995
    Date of Patent: February 2, 1999
    Inventors: Stephen F. Badylak, Sherry Voytik, George Boder
  • Patent number: 5830685
    Abstract: A novel bronchial or bronchiolar epithelial cell from normal neonatal mammalian lung has been isolated, established and maintained for multiple passages in the absence of serum, without undergoing crisis or senescence. By careful manipulation of the nutritional/hormonal microenvironment we have been able to select, from a heterogeneous population, a single epithelial cell type which can maintain highly differentiated features in vitro. This cell type has characteristics of bronchiolar epithelial cells. A clonal line, RL-65, has been selected and observed for more than 3 years in continuous culture. It has been characterized by ultrastructural, morphological and biochemical criteria.
    Type: Grant
    Filed: July 16, 1992
    Date of Patent: November 3, 1998
    Assignee: Genentech, Inc.
    Inventors: Jennie P. Mather, Penelope E. Roberts
  • Patent number: 5773241
    Abstract: This invention relates to the extraction of biological compounds from plants and animals and to the preparation and tinctures and essences from the extracted materials. The materials are extracted using alcoholic and/or phosphate buffered saline solutions. The extraction step can be performed repeatedly on the residue from the previous step. The rich solution resulting from the extraction can be freeze dried for further use or employed as a fermentation feed. The fermenter product can be freeze dried for further use. The invention also makes use of the residues resulting from the extraction and fermentation reactions.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: June 30, 1998
    Inventor: Arthur Dale Ericsson
  • Patent number: 5736345
    Abstract: A novel bronchial or bronchiolar epithelial cell from normal neonatal mammalian lung has been isolated, established and maintained for multiple passages in the absence of serum, without undergoing crisis or senescence. By careful manipulation of the nutritional/hormonal microenvironment we have been able to select, from a heterogeneous population, a single epithelial cell type which can maintain highly differentiated features in vitro. This cell type has characteristics of bronchiolar epithelial cells. A clonal line, RL-65, has been selected and observed for more than 3 years in continuous culture. It has been characterized by ultrastructural, morphological and biochemical criteria.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: April 7, 1998
    Assignee: Genentech, Inc.
    Inventors: Jennie P. Mather, Penelope E. Roberts
  • Patent number: 5691202
    Abstract: This invention relates to a serum-free eukaryotic cell culture medium supplement. The supplement comprises carbon sources, vitamins, inorganic salts, amino acids and a protein digest.The medium supplement of the present invention enables the maintenance of mammalian cell cultures at cell densities equal to or greater than that obtained with batch culture methods while increasing longevity and productivity.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: November 25, 1997
    Assignee: Genzyme Corporation
    Inventors: Nick C. Wan, Jason C. Goodrick
  • Patent number: 5607852
    Abstract: A live, attenuated varicella zoster virus vaccine is produced with enhanced yield of VZV. The new process makes mass production of a live VZV vaccine more practical. In addition, optimized monoloyer cell culture conditions provide a process for maximizing monolayer cell density which is useful for enhancing viral vaccine production. According to this process, cell densities approaching 500,000 cells/cm.sup.2 are routinely achieved in conventional culture vessels.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: March 4, 1997
    Assignee: Merch & Co., Inc.
    Inventors: Philip J. Provost, David L. Krah, Paul A. Friedman